Manufacturing capabilities and supply chain infrastructure are critical determinants of the phage therapy market's ability to scale from experimental treatments to routine clinical care. The production of therapeutic phages requires specialized GMP facilities that can handle live biological products with strict contamination controls and quality assurance protocols. Currently, limited GMP...